论文部分内容阅读
目的探究丙硫氧嘧啶治疗自身免疫性甲状腺疾病(AITD)对趋化因子[巨噬细胞炎性蛋白(MIP)-1α、MIP-1β及单核细胞趋化蛋白-1(MCP-1)]表达的影响。方法随机选取2012年4月至11月收治的AITD患者100例,依照其入院先后顺序将患者分为观察组(60例)与对照组(40例)。对照组患者采用常规131I放射治疗,观察组患者在对照组基础上给予丙硫氧嘧啶药物治疗,治疗周期为8周。观察两组患者治疗前后血清游离三碘甲腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)、甲状腺过氧化物酶抗体(TPOAb)与甲状腺球蛋白抗体(TGAb)水平及趋化因子MIP-1α、MIP-1β及MCP-1在患者甲状腺组织中(穿刺活检获取)的阳性表达情况。结果治疗8周后两组患者血清FT3、FT4、TGAb及TPOAb水平均较治疗前降低(P均<0.05),TSH升高(P均<0.05);且观察组患者的改善优于对照组(P均<0.05)。治疗8周后与治疗前比较,MIP-1α、MIP-1β及MCP-1阳性表达率在观察组患者均明显降低(P均<0.05),对照组稍有降低,但差异无统计学意义(P均>0.05);观察组MIP-1α、MIP-1β阳性表达率明显低于对照组(P均<0.05)。结论丙硫氧嘧啶在AITD的治疗中可有效改善甲状腺激素水平及其自身抗体,临床疗效可能与有效抑制趋化因子MIP-1α、MIP-1β的表达有关。
Objective To investigate the effect of propylthiouracil on the expression of chemokines (MIP-1α, MIP-1β and MCP-1) in patients with autoimmune thyroid disease (AITD) The impact of expression. Methods A total of 100 patients with AITD admitted from April 2012 to November 2012 were randomly divided into observation group (60 cases) and control group (40 cases). Patients in the control group received conventional 131I radiotherapy. Patients in the observation group were given propylthiouracil drugs on the basis of the control group, and the treatment period was 8 weeks. The levels of serum free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin (TSH), thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TGAb) And the positive expression of chemokines MIP-1α, MIP-1β and MCP-1 in patients with thyroid tissue (biopsy). Results After 8 weeks of treatment, the levels of FT3, FT4, TGAb and TPOAb in both groups were significantly lower than those before treatment (all P <0.05) and TSH (all P <0.05); and the improvement in observation group was better than that in control group P <0.05). After 8 weeks of treatment, the positive rates of MIP-1α, MIP-1β and MCP-1 in the observation group were significantly lower than those in the control group (all P <0.05), while the control group was slightly lower, but the difference was not statistically significant P> 0.05). The positive rates of MIP-1α and MIP-1β in the observation group were significantly lower than those in the control group (all P <0.05). Conclusions Propylthiouracil can effectively improve the level of thyroid hormone and its autoantibodies in the treatment of AITD. The clinical efficacy may be related to the inhibition of the expression of chemokines MIP-1α and MIP-1β.